Drugs / GDC-7035
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06619587 | Nov 2024 → May 2028 expected | cancer | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-7035 | “Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035” NCT06619587 ↗ |